(Q40549041)

21 September 2017

1 reference

title

New antiepileptic drugs--an explosion of activity (English)

1 reference

21 September 2017

J P Leach

1

1 reference

21 September 2017

M J Brodie

series ordinal

2

1 reference

21 September 2017

publication date

1 March 1995

1 reference

Seizure-European Journal of Epilepsy

21 September 2017

published in

1 reference

21 September 2017

volume

4

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

5-17

1 reference

Changing view of prognosis of epilepsy

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Established anticonvulsants and treatment of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Management of epilepsy during pregnancy and lactation

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Drug interactions in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Microdysgenesis in resected temporal neocortex: Incidence and clinical significance in focal epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Anatomy, physiology, and pathology of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A selective decrease in the number of GABAergic somata occurs in pre-seizing monkeys with alumina gel granuloma

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Hippocampal plasticity in childhood epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Cellular mechanisms of epilepsy: a status report

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Drug treatment of epilepsy. Outlines, criticism and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Clinical pharmacology of vigabatrin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Interaction between vigabatrin and phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

1 reference

7 January 2021

Vigabatrin and lamotrigine in refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Controlled trial of lamotrigine (Lamictal) for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Outcomes of add-on treatment with lamotrigine in partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Human Safety of Lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Gabapentin actions on ligand- and voltage-gated responses in cultured rodent neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

1 reference

7 January 2021

Gabapentin as an antiepileptic drug in man

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Double-blind study of Gabapentin in the treatment of partial seizures.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Long-term treatment with gabapentin for partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. The US Gabapentin Study Group No. 5

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Oxcarbazepine: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Oxcarbazepine does not affect the anticoagulant activity of warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Oxcarbazepine does not interact with cimetidine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Possible interaction between oxcarbazepine and an oral contraceptive

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Comparison of oxcarbazepine and carbamazepine: a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate: a new antiepileptic drug

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Effect of felbamate on plasma levels of carbamazepine and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Discontinuation of phenytoin and carbamazepine in patients receiving felbamate

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate for partial seizures: results of a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate: a clinical trial for complex partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate monotherapy: controlled trial in patients with partial onset seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome).

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Felbamate monotherapy for partial-onset seizures: an active-control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Stiripentol in acute/chronic efficacy tests in monkey model.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Stiripentol in atypical absence seizures in children: an open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

Comparative pharmacokinetics of the newer antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2805%2980074-3

7 January 2021

10.1016/S1059-1311(05)80074-3

Identifiers

DOI

1 reference

21 September 2017

1 reference